The Effect Size Is 0.81. The Number That Decides the Business Is 6.4 Hours.
Effect size 0.81 settles the efficacy question. The number that decides the business is 6.4 hours of supervised monitoring per dose.
Effect size 0.81 settles the efficacy question. The number that decides the business is 6.4 hours of supervised monitoring per dose.
Six suits against small peptide sellers is not a strategy for a market spanning a hundred countries. It is a demonstration attached to an appeal.
Dupixent, Nucala and Vyvdura were all cut after adding an indication. In Japan the trigger for a price cut is the drug reaching more patients.
These were not patents on a drug. They were patents on the methods used to find one, and Black Diamond has agreed to pay rather than test them.
Both sides are fighting over a number nobody can produce. The evaluation went underneath them and named the reason: the service is inside the price.
Committing 30% of a health ministry’s requirement at agreed prices means deciding not to buy the cheapest product. Somebody is paying for that.
Freenome defined its population by the failure of the existing pathway, not by anything measurable in the patient. That is the decision worth reading.
BD is not testing a product against a competitor. It is testing whether an indication can be brought into existence, with no label, code or precedent.
Two patients with severe aphasia solved formal logic problems as well as controls. The language network stayed quiet through both reasoning types.
Nobody gained insurance access. Designation is the gate before the negotiation. The real story is that both lead technologies remove a specialist.